135 related articles for article (PubMed ID: 15968389)
1. Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy.
Baru M; Carmel-Goren L; Barenholz Y; Dayan I; Ostropolets S; Slepoy I; Gvirtzer N; Fukson V; Spira J
Thromb Haemost; 2005 Jun; 93(6):1061-8. PubMed ID: 15968389
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of haemostatic efficacy of plasma-derived FVIII by formulation with PEGylated liposomes.
Dayan I; Robinson M; Baru M
Haemophilia; 2009 Sep; 15(5):1006-13. PubMed ID: 19486171
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes.
Yatuv R; Dayan I; Carmel-Goren L; Robinson M; Aviv I; Goldenberg-Furmanov M; Baru M
Haemophilia; 2008 May; 14(3):476-83. PubMed ID: 18393980
[TBL] [Abstract][Full Text] [Related]
5. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes.
Spira J; Plyushch OP; Andreeva TA; Andreev Y
Blood; 2006 Dec; 108(12):3668-73. PubMed ID: 16888098
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A.
Spira J; Plyushch OP; Andreeva TA; Khametova RN
Thromb Haemost; 2008 Sep; 100(3):429-34. PubMed ID: 18766258
[TBL] [Abstract][Full Text] [Related]
7. The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia.
Yatuv R; Robinson M; Dayan-Tarshish I; Baru M
Int J Nanomedicine; 2010 Sep; 5():581-91. PubMed ID: 20856833
[TBL] [Abstract][Full Text] [Related]
8. Enhanced efficacy of recombinant FVIII in noncovalent complex with PEGylated liposome in hemophilia A mice.
Pan J; Liu T; Kim JY; Zhu D; Patel C; Cui ZH; Zhang X; Newgren JO; Reames A; Canivel D; Jesmok G; Pierce GF; Sommer JM; Jiang H
Blood; 2009 Sep; 114(13):2802-11. PubMed ID: 19654409
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes; a case of FVIII, FVIIa and G-CSF.
Yatuv R; Robinson M; Dayan I; Baru M
Expert Opin Drug Deliv; 2010 Feb; 7(2):187-201. PubMed ID: 20095942
[TBL] [Abstract][Full Text] [Related]
10. Longer-acting factor VIII to overcome limitations in haemophilia management: the PEGylated liposomes formulation issue.
Di Minno G; Cerbone AM; Coppola A; Cimino E; Di Capua M; Pamparana F; Tufano A; Di Minno MN
Haemophilia; 2010 Jan; 16 Suppl 1():2-6. PubMed ID: 20059562
[TBL] [Abstract][Full Text] [Related]
11. Binding of proteins to PEGylated liposomes and improvement of G-CSF efficacy in mobilization of hematopoietic stem cells.
Yatuv R; Carmel-Goren L; Dayan I; Robinson M; Baru M
J Control Release; 2009 Apr; 135(1):44-50. PubMed ID: 19135487
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.
Brand B; Gruppo R; Wynn TT; Griskevicius L; Lopez Fernandez MF; Chapman M; Dvorak T; Pavlova BG; Abbuehl BE
Haemophilia; 2016 Jul; 22(4):e251-8. PubMed ID: 27328112
[TBL] [Abstract][Full Text] [Related]
13. Haemostatic response to factor VIII administration in patients with haemophilia A measured by thrombin generation and correlation with factor concentrate use.
Hugenholtz GC; Luddington R; Baglin T
Haemophilia; 2016 Jan; 22(1):e42-5. PubMed ID: 26388112
[No Abstract] [Full Text] [Related]
14. Desmopressin treatment combined with clotting factor VIII concentrates in patients with non-severe haemophilia A: protocol for a multicentre single-armed trial, the DAVID study.
Schütte LM; Cnossen MH; van Hest RM; Driessens MHE; Fijnvandraat K; Polinder S; Beckers EAM; Coppens M; Eikenboom J; Laros-van Gorkom BAP; Meijer K; Nieuwenhuizen L; Mauser-Bunschoten EP; Leebeek FWG; Mathôt RAA; Kruip MJHA
BMJ Open; 2019 Apr; 9(4):e022719. PubMed ID: 31015264
[TBL] [Abstract][Full Text] [Related]
15. Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.
Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
Biopharm Drug Dispos; 2016 Oct; 37(7):409-420. PubMed ID: 27418232
[TBL] [Abstract][Full Text] [Related]
16. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.
Powell JS; Nugent DJ; Harrison JA; Soni A; Luk A; Stass H; Gorina E
J Thromb Haemost; 2008 Feb; 6(2):277-83. PubMed ID: 18039351
[TBL] [Abstract][Full Text] [Related]
17. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.
Mei B; Pan C; Jiang H; Tjandra H; Strauss J; Chen Y; Liu T; Zhang X; Severs J; Newgren J; Chen J; Gu JM; Subramanyam B; Fournel MA; Pierce GF; Murphy JE
Blood; 2010 Jul; 116(2):270-9. PubMed ID: 20194895
[TBL] [Abstract][Full Text] [Related]
18. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII.
Zollner S; Raquet E; Claar P; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
Thromb Res; 2014 Jul; 134(1):125-31. PubMed ID: 24814969
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVIII-FS) in patients with haemophilia A: a long-term, multicentre clinical study in Japan.
Yoshioka A; Shima M; Fukutake K; Takamatsu J; Shirahata A;
Haemophilia; 2001 May; 7(3):242-9. PubMed ID: 11380627
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94-9027) for haemophilia A.
Gu JM; Ramsey P; Evans V; Tang L; Apeler H; Leong L; Murphy JE; Laux V; Myles T
Haemophilia; 2014 Jul; 20(4):593-600. PubMed ID: 24471985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
